Author:
Hwang Yeonggwang,Kim Hyoung-Chun,Shin Eun-Joo
Funder
National Research Foundation of Korea
Reference112 articles.
1. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors;Bendell;J. Clin. Oncol.,2012
2. Buparlisib in breast cancer;Sirohi;Future Oncol.,2015
3. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy;Zhao;Acta Pharm. Sin. B,2017
4. Benefits versus risk profile of buparlisib for the treatment of breast cancer;Patsouris;Expert Opin. Drug Saf.,2019
5. Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial;Wen;J. Clin. Oncol.,2019
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献